Juan-Luis Onieva-Zafra

8PUBLICATIONS
19CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 28, 2026
Clinical outcomes and blood-based biomarkers across two SABR-treated metastatic settings: oligoprogression under immune checkpoint inhibition and oligometastatic disease.

|Mar 31, 2026
Integrating tumor and immune cell transcriptomics to predict immune checkpoint inhibitor primary resistance in metastatic melanoma.

Juan Luis Onieva, Elisabeth Pérez-Ruiz, Ville Vilkki

|Jan 16, 2026
Integrative multiomic profiling of cfDNA methylation and EV-miRNAs identifies immunotherapy-outcome molecular subtypes in NSCLC.

Juan Luis Onieva, Elisabeth Pérez-Ruiz, Laura Cristina Figueroa-Ortiz

|Apr 27, 2024
Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer.

Juan Zafra, Juan Luis Onieva, Javier Oliver

|Jul 14, 2023
Fluorometric Quantification of Total Cell-Free DNA as a Prognostic Biomarker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade.

Javier Oliver, Juan Luis Onieva, María Garrido-Barros

|Oct 27, 2022
Association of Circular RNA and Long Non-Coding RNA Dysregulation with the Clinical Response to Immune Checkpoint Blockade in Cutaneous Metastatic Melanoma.

Javier Oliver, Juan Luis Onieva, Maria Garrido-Barros

Pageof 2

Frequent Collaborators

6 joint publications

Elisabeth Pérez-Ruiz

5 joint publications

Isabel Barragán

4 joint publications

Javier Oliver

3 joint publications

Miguel-Ángel Berciano-Guerrero